Post Market Clinical Follow-Up Study for EVOLUTION® NitrX™ Keeled Tibia and EVOLUTION® NitrX™ CS/CR Femur With Cruciate Sacrificing Insert

Osteoarthritis Clinical Trial

Official title:

Post Market Clinical Follow-Up Study for EVOLUTION® NitrX™ Keeled Tibia and EVOLUTION® NitrX™ CS/CR Femur With Cruciate Sacrificing Insert

Clinical Trial Details — Status: Enrolling by invitation

Administrative data

• NCT number: NCT04816773
• Other study ID #: 20K001
• Status: Enrolling by invitation
• Start date: January 27, 2022
• Est. completion date: January 2035

Study information

• Verified date: March 2024
• Source: MicroPort Orthopedics Inc.
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

MicroPort Orthopedics Inc. (MPO) plans to market the EVOLUTION® NitrX™ Non-Porous Keeled Tibia and EVOLUTION® NitrX™ CS/CR Non-Porous Femur with the EVOLUTION® Cruciate Sacrificing (CS) Tibial Insert globally, including in the European Union (EU). MPO is conducting this post market clinical follow-up (PMCF) study to evaluate the safety and effectiveness of the EVOLUTION® NitrX™ Non-Porous Keeled Tibia and EVOLUTION® NitrX™ CS/CR Non-Porous Femur. These components are used along with the EVOLUTION® Cruciate Sacrificing (CS) Tibial Insert components that is marketed in the European Union (EU). This type of data collection is required by regulatory authorities for all TKA devices that do not have medium to long-term clinical evidence available.

Recruitment information / eligibility

• Status: Enrolling by invitation
• Enrollment: 150
• Est. completion date: January 2035
• Est. primary completion date: August 2034
• Accepts healthy volunteers: No
• Gender: All
• Age group: 21 Years and older

Eligibility

Inclusion Criteria:

1. Has previously undergone or currently has determined to undergo a primary TKA with the specified combination of components: EVOLUTION® NitrX™ CS/CR Non-Porous Femur, EVOLUTION® NitrX™ Non-Porous Keeled Tibia and EVOLUTION® CS Tibial Insert

2. Has previously undergone or currently has determined to undergo a primary TKA for any of the following:

• non-inflammatory degenerative joint disease including osteoarthritis, traumatic arthritis, or avascular necrosis;

• inflammatory degenerative joint disease including rheumatoid arthritis;

• correction of functional deformity;

3. Willing to voluntarily sign the informed consent form

4. Willing and able to comply with the protocol, able to read and complete the required forms, and willing and able to adhere to the requirements of the protocol through the 10-year postoperative follow-up visit.

5. Previously implanted subjects must be enrolled within 14 months of their primary TKA implantation.

Prospective enrollment of a previously unimplanted contralateral knee is permitted in this study provided:

1. the specified combination of components (EVOLUTION® NitrX™ CS/CR Non-Porous Femur, EVOLUTION® NitrX™ Non-Porous Keeled Tibia and EVOLUTION® CS Tibial Insert) are used,

2. all other aspects of the Inclusion/Exclusion Criteria are satisfied,

3. enrollment does not exceed the subject count specified in the Clinical Trial Agreement, and

4. the subject agrees to a second Informed Consent document and data collection specific to the second TKA.

Bilateral subjects can have both TKAs enrolled in the study provided:

1. the specified combination of components (EVOLUTION® NitrX™ CS/CR Non-Porous Femur, EVOLUTION® NitrX™ Non-Porous Keeled Tibia and EVOLUTION® CS Tibial Insert) were implanted in both,

2. all other aspects of the Inclusion/Exclusion Criteria are satisfied,

3. enrollment does not exceed the subject count specified in the Clinical Trial Agreement, and

4. the subject agrees to a second Informed Consent document and data collection specific to the second TKA.

Bilateral implantation can occur at different time periods for the same subject.

Exclusion Criteria:

1. Skeletally immature (less than 21 years of age) at time of implantation

2. Has or had an overt infection at the time of implantation

3. Has or had a distant foci of infections (which may cause hematogenous spread to the implant site) at the time of implantation

4. Has or had a rapid disease progression as manifested by joint destruction or bone absorption apparent on roentgenogram at the time of implantation

5. Has or had inadequate neuromuscular status (e.g., prior paralysis, fusion, and/or inadequate abductor strength), poor bone stock, poor skin coverage around the joint which would make the procedure unjustifiable

6. Currently enrolled in another clinical investigation which could affect the endpoints of this protocol

7. Has documented substance abuse issues

8. Has an emotional or neurological condition that would pre-empt their ability or willingness to participate in the study

9. Currently incarcerated or has impending incarceration

10. Has a medical condition, as judged by the Investigator, that would interfere with the subject's ability to comply with the requirements of the protocol

Related Conditions & MeSH terms

• Arthritis Knee
• Avascular Necrosis
• Joint Diseases
• Necrosis
• Osteoarthritis

Intervention

Device:
• EVOLUTION® NitrX™
EVOLUTION® NitrX™ Keeled Tibia and EVOLUTION® NitrX™ CS/CR Femur With Cruciate Sacrificing Insert

Locations

Country	Name	City	State
United Kingdom	MSK Doctors, The Keep Clinic	Grantham	Lincolnshire
United States	Sah Orthopaedic Associates	Fremont	California

Sponsors (1)

Lead Sponsor	Collaborator
MicroPort Orthopedics Inc.

Countries where clinical trial is conducted

United States,  United Kingdom, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Component Survivorship of the EVOLUTION® NitrX™ Non-Porous Keeled Tibia	The primary endpoint is to evaluate component survivorship of the EVOLUTION® NitrX™ Non-Porous Keeled Tibia out to 10 years follow-up. Percentage of knees survived with no revisions or replacement at 10-year	10 years post-operative
Primary	Component Survivorship of the EVOLUTION® NitrX™ CS/CR Non-Porous Femur	The primary endpoint is to evaluate component survivorship of the EVOLUTION® NitrX™ CS/CR Non-Porous Femur out to 10 years follow-up. Percentage of knees survived with no revisions or replacement at 10-year.	10 years post-operative
Primary	Component Survivorship of the EVOLUTION® NitrX™ MP CS tibial inserts	The primary endpoint is to evaluate component survivorship of the EVOLUTION® NitrX™ MP CS tibial inserts out to 10 years follow-up. Percentage of knees survived with no revisions or replacement at 10-year.	10 years post-operative
Secondary	Functional Scores	To assess functional scores utilizing Knee Injury and Osteoarthritis Outcome Score (KOOS).	10 years post-operative
Secondary	Functional Scores	To assess functional scores utilizing EQ-5D-5L.	10 years post-operative
Secondary	Functional Scores	To assess functional scores utilizing Forgotten Joint Score (FJS).	10 years post-operative
Secondary	Subject Satisfaction	To assess subject satisfaction with their TKA procedure via the Satisfaction Survey.	10 years post-operative
Secondary	Radiolucencies	To assess the presence of radiolucencies surrounding the implanted femoral and tibial components present in each of the 17 zones.	10 years post-operative
Secondary	To assess subject safety: Adverse Events	To assess safety of the EVOLUTION® NitrX™ system through device-related adverse event findings and/or adverse device effects during follow-up visits.	1, 3, 5, 7, 10 years
Secondary	To assess device tolerability within subject: Adverse Events	To assess tolerability of the EVOLUTION® NitrX™ system service-related adverse event findings and/or adverse device effects during follow-up visits.	10 years post-operative